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Abstract CIN85 is a multidomain sca¡old protein involved in
downregulation of receptor tyrosine kinases. Here we show that
disabled-2 (Dab2), an endocytic adaptor molecule implicated in
clathrin-coat assembly, associates with CIN85 in mammalian
cells. All three SH3 domains of CIN85 were able to bind to
the PKPAPR peptide in the carboxyl-terminal part of Dab2,
possibly enabling CIN85 to simultaneously interact with multi-
ple Dab2 molecules. CIN85 association with Dab2 is essential
for its recruitment to clathrin coat and appears to be modulated
by growth factor stimulation. Dab2 and clathrin dissociated
from CIN85 following growth factor treatment, enabling other
molecules, such as Cbl, to bind to CIN85. Taken together, our
data indicate a dynamic interplay between CIN85 and its e¡ec-
tors during endocytosis of receptor tyrosine kinases.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Growth factor binding to receptor tyrosine kinases (RTKs)
triggers signaling cascades that elicit diverse biological re-
sponses, such as cell proliferation, migration, adhesion, di¡er-
entiation or apoptosis [1]. Activation of receptors also results
in their internalization through clathrin-coated pits, which is
considered as a main mechanism of receptor downregulation
and cessation of signaling [2]. The Cbl family of ubiquitin
ligases are believed to be among the most important regula-
tors of RTK tra⁄cking [3,4]. Cbl mediates multiple mono-
ubiquitination of activated receptors at the cell membrane, tar-
geting them for endocytosis and lysosomal degradation [5,6].
In addition, Cbl proteins, independently on their ubiquitin
ligase activity, recruit an adaptor molecule CIN85, bound to
endophilins, in the complex with activated RTKs [7^9]. This
constitutes a critical step for receptor internalization and traf-
¢cking [8,9].
CIN85 (Cbl interacting protein of 85 kDa) is a multidomain
adaptor molecule, functioning in the assembly of protein com-
plexes that participate in numerous signaling networks [10]. It
is also involved at distinct steps of clathrin-mediated receptor
endocytosis, as well as being sorted together with receptors for
lysosomal degradation [11]. Moreover, CIN85 Src homology 3
(SH3) domains have recently been shown to recognize a novel
PxxxPR motif, present in Cbl as well as in numerous proteins
implicated in endocytic tra⁄cking [12] (and unpublished ob-
servations). Thus CIN85 has a potential to regulate the as-
sembly of a large receptor-associated protein network upon
growth factor stimulation.
Dab2/DOC-2 (disabled-2/di¡erentially-expressed in ovarian
carcinoma) is another multidomain protein, acting as an en-
docytic adaptor [13]. Dab2 binds to clathrin and is able to
regulate its assembly in vitro, and moreover interacts with
clathrin adaptor protein AP-2 and phosphoinositides [13].
Conditional deletion of Dab2 in mice leads to reduced clath-
rin-coated pits and impaired transport of transmembrane re-
ceptors in the proximal tubule of kidney [14].
In this report we demonstrate that Dab2 associates with the
SH3 domains of CIN85 via a conserved PxxxPR motif in its
carboxyl-terminus. Moreover, Dab2 links CIN85 with clathrin
complexes in mammalian cells. Epidermal growth factor re-
ceptor (EGFR) activation results in increased Cbl/CIN85 as-
sociation [8], which in turn leads to disruption of CIN85/
Dab2 complexes. Thus CIN85 functions as an endocytic
adaptor, not only by binding to RTK/Cbl complexes and
numerous endocytic proteins, but also being a component of
a complex protein network that accompanies clathrin-coated
vesicles formation.
2. Materials and methods
2.1. Products, antibodies and expression vectors
EGF was purchased from Intergen; mouse anti-Dab2 (p96) and
mouse anti-clathrin heavy chain antibodies were from Transduction
Laboratories, mouse anti-HA were form Roche and mouse anti-
FLAG M2 antibodies were from Sigma. Anti-Cbl (RING) and anti-
CIN85 (CT) antibodies were used as previously described [8,9]. All
constructs of Cbl and CIN85 were described previously [8,9,12]. Dab1
and Dab2 constructs were from Philip H. Howe.
2.2. Yeast two-hybrid system screening
The screening procedure was performed as previously described
[8,9].
2.3. Site-directed mutagenesis
Dab2 R699A mutant was generated by PCR using Quick Change
(Stratagene).
2.4. Cell culture and transfections
HEK293T, NIH SAA (NIH-EGFR) and NIH3T3 cells were used
as described previously [8,9]. Cells were transfected with Lipofectam-
ine reagent (Invitrogen) following manufacturer’s instructions. Where
indicated, 30 h after transfection cells were starved for additional 12 h
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and stimulated with 100 ng ml31 EGF for indicated times. Cells were
lysed in ice-cold 1% Triton X-100 lysis bu¡er (pH 7.4, 50 mM
HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol)
containing a cocktail of protease and phosphatase inhibitors. The
lysates were cleared by centrifugation at 13 000 rpm for 20 min at 4‡C.
2.5. Peptide synthesis and peptide binding assays
All peptides were synthesized and used as previously described [12].
2.6. Biochemical assays
Glutathione S-transferase (GST) binding assays, immunoprecipita-
tion and immunoblotting were performed as reported before [9].
3. Results
3.1. Dab2 interacts with the three SH3 domains of CIN85
In order to unravel novel functions for CIN85 in formation
of signaling networks, we screened human thymus cDNA li-
brary with the full size CIN85 as bait. Two of the positive
clones contained the carboxyl-terminus of Dab2, encoding its
proline-rich region. Subsequently, yeast clones expressing ei-
ther three SH3 domains of CIN85 (SH3), a proline-rich region
with the coiled-coil domain (PCc), full size CIN85 or an
empty vector were transformed with the Dab2 library clone,
and interactions were checked by the ability of clones to grow
on selective agars and by ¢lter lift assays. The SH3 domains
and the full size molecule, but not the PCc domain of CIN85
or an empty bait vector, bound to Dab2 in yeast cells (Fig.
1A).
To con¢rm these results in mammalian cells, we performed
pull-down assays with GST-fusion proteins encoding three
SH3 domains (SH3) or the proline-rich region with the
coiled-coil domain (PCc) of CIN85. To this aim we used ly-
sates of HEK293T cells transfected with Dab2, or its neuron-
speci¢c relative Dab1 [15]. Three SH3 domains of CIN85
interacted strongly with both Dab2 and Dab1, whereas no
interaction was detected with an empty GST or with the
GST-fusion construct encoding the proline-rich coiled-coil
part of CIN85 (Fig. 1B). In order to further characterize
interactions between the SH3 domains of CIN85 and Dab2,
we compared GST-fusion proteins containing individual
(SH3-A, SH3-B, SH3-C), combination of two (SH3-AB and
SH3-BC), or all three (SH3-ABC) SH3 domains of CIN85, for
their ability to bind to Dab2 expressed in 293T cells. All single
SH3 domains of CIN85 bound Dab2 to the similar extend,
whereas SH3-AB, SH3-BC and a fusion protein containing all
three SH3 domains (SH3-ABC), associated with Dab2 more
potently. Thus multiple SH3 domains of CIN85 are required
for the most e⁄cient binding to Dab2 (Fig. 1C). These data
point out that all SH3 domains of CIN85 are implicated in
interacting with Dab2 molecules, which resembles a mecha-
nism of CIN85-Cbl interaction [12].
3.2. Identi¢cation of CIN85 binding site in the
carboxyl-terminus of Dab2
The carboxyl-terminal part of Dab2 was su⁄cient to medi-
ate interaction with CIN85 in yeast. It contains several pro-
line-rich sequences, and among them two PxxxPR motifs,
which constitute potential recognition sites for the SH3 do-
mains of CIN85 [12]. One of them (PKPAPR) shared high
similarity with the CIN85 binding motifs in Cbl and Cbl-b
(PKPFPR and PKPRPR), respectively [12]. Binding of CIN85
to the puri¢ed Dab2 peptide NKINEPPKPAPRQGVLLG
was further assessed by in vitro peptide binding assays. In-
creasing amounts of CIN85 were precipitated in a dose-depen-
dent manner with the Dab2 peptide, however the binding was
much weaker when compared to the Cbl-derived peptide (Fig.
2A). The other potential CIN85-SH3 domains’ recognition
Fig. 1. Dab2 interacts with the SH3 domains of CIN85. A: Yeast
clones expressing full size CIN85, 3SH3 or PCc (proline coiled-coil)
domains were transformed with Dab2 cDNA and streaked on selec-
tive agar plates (-Leu-Trp-His+3-aminotriazole). Growth rate (left)
and L-galactosidase activity in a ¢lter lift assay (right) are shown.
B: Equal amounts of lysates from HEK293T cells transiently trans-
fected with Dab2 or Dab1 were incubated with GST alone or GST-
fusion forms of CIN85 immobilized on glutathione Sepharose beads.
Amounts of precipitated Dab1 and Dab2 are visualized in the upper
panel (anti-FLAG Dab2 and anti-HA Dab1), while the lower panel
shows the levels of used GST constructs. C: Equal amounts of ly-
sates from HEK293T cells transiently transfected with Dab2 were
incubated with GST alone or di¡erent GST-fusion proteins encod-
ing all single, combinations of double or triple SH3 domains of
CIN85 immobilized on glutathione Sepharose beads. Amounts of
precipitated Dab2 are visualized in the upper panel (anti-FLAG
Dab2), while the lower panel shows the levels of used GST con-
structs.
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site present in Dab2, PQPPPR, did not bind to CIN85 in the
same assays (data not shown). Subsequently, we mutated ar-
ginine in the PKPAPR sequence and have shown that the
R699A mutation (corresponding to human Dab2 sequence)
completely abrogated the interaction of Dab2 with the GST-
SH3 domains of CIN85 (Fig. 2B).
To further con¢rm that the PKPAPR sequence is critical
for mediating interaction with CIN85, we disrupted this motif
in full size Dab2 molecule, by mutating arginine 699 to ala-
nine. Indeed, the co-precipitation between CIN85 and Dab2
was impaired when the R699A Dab2 mutant was used instead
of the wild-type protein (Fig. 2C). Taken together, we have
identi¢ed a conserved binding site for the SH3 domains of
CIN85 in the C-terminal part of Dab2 and Dab1 (PxPAPR),
which is highly homologous to the CIN85 interacting motif in
the C-terminus of Cbl and Cbl-b [12].
3.3. Interactions with Dab2 link CIN85 to clathrin-coated
vesicles
Dab2 has been shown to potently associate with clathrin,
Fig. 2. The PKPAPR sequence in Dab2 is responsible for CIN85 binding. A: In vitro peptide binding assay. The left panel lists the peptides
used: the Dab2 proline-rich peptide encompasses amino acids 707 to 724 from mouse Dab2 p96 splice form, the c-Cbl peptide (814) was previ-
ously described [12]. The amino acid sequences of both peptides are presented and the conserved PxxxPR motif is emphasized in bold. Lysates
of 293T cells transfected with CIN85 were incubated with the indicated amounts of the peptides coupled to the SulfoLink gel (right panel).
After recovery of the bound material, detection was performed by immunoblotting with anti-CIN85 antibodies. B: Equal amounts of lysates
from HEK293T cells transiently transfected with the wild-type Dab2 or Dab2 R699A mutant were incubated with GST alone or GST-3SH3
domains of CIN85 immobilized on glutathione Sepharose beads. The amounts of precipitated Dab2 are visualized in the upper panel (anti-
Dab2), the lower panel shows the levels of used GST constructs (Ponceau staining). C: 293T cells were transiently transfected with CIN85 and
the wild-type Dab2 or the R699A mutant. Lysates were immunoprecipitated with the indicated antibodies, and after recovery of the bound ma-
terial, detection was performed by immunoblotting with anti-Dab2 or anti-CIN85 antibodies.
FEBS 27745 23-10-03
K. Kowanetz et al./FEBS Letters 554 (2003) 81^87 83
both directly and indirectly via its interactions with AP-2
[13,16]. Therefore we tested whether Dab2 constitutes a link
between clathrin and CIN85 in mammalian cells. Indeed,
CIN85, Dab2 and clathrin heavy chain were detected in one
protein complex. GST-fused 3SH3 domains of CIN85 were
associating with endogenous clathrin in NIH SAA cells,
whereas no binding was detected for CIN85 GST-PCc or an
empty GST (Fig. 3A). Interestingly, there was a decrease in
the amount of Dab2 as well as of clathrin heavy chain co-
precipitated with GST-CIN85 3SH3 domains upon growth
factor stimulation (Fig. 3A). Thus, CIN85 can be found in
a complex with clathrin heavy chain, and this is at least in
part due to its direct binding to Dab2. In accordance with our
hypothesis, transfection of the Dab2 R699A mutant in 293T
cells led to a signi¢cant decrease in the amount of endogenous
clathrin heavy chain bound to the GST-fused 3SH3 domains
of CIN85, as compared to the cells transfected with the wild-
type Dab2 (Fig. 3B).
We have also observed that CIN85 contains three motifs in
its C-terminal part, resembling the so-called ‘clathrin box’,
found in numerous clathrin binding proteins [17]. However,
we were not able to detect any direct interaction between
CIN85 and clathrin heavy chain (data not shown).
3.4. Dab2 dissociates from CIN85 following EGFR stimulation
and is replaced by Cbl
We have previously shown that CIN85 associates with Cbl
and EGFRs following ligand stimulation, and remains in this
complex during receptor tra⁄cking to the lysosome [8,11].
Since CIN85-SH3 domain-mediated interactions can be
modulated by growth factor stimulation [8], and additionally
Src and Grb2 interact with the Dab2 proline-rich region in a
ligand-dependent manner [18,19], we tested whether binding
of CIN85 to Dab2 is a¡ected by EGFR activation. To this
aim, HEK293T cells co-expressing FLAG-tagged Dab2 and
CIN85 were stimulated with EGF for indicated time periods,
then lysed and subjected to immunoprecipitation with anti-
FLAG or anti-CIN85 antibodies. Binding between CIN85
and Dab2 was observed in unstimulated cells, was signi¢-
cantly decreased after 2 min of EGF stimulation, and com-
pletely undetectable after 20 min of stimulation (Fig. 4A).
Importantly, we were able to detect complex formation be-
tween endogenous Dab2 and CIN85 in NIH SAA cells (Fig.
4B). Analogously to the overexpression experiments, there
was a signi¢cant decrease in the amount of Dab2 bound to
CIN85 following cells’ stimulation with EGF (Fig. 4B, right
panel).
Since we were not able to detect tyrosine phosphorylation
of Dab2 following EGF stimulation (data not shown), its li-
gand-dependent dissociation from CIN85 might be mediated
by other mechanisms, such as Dab2/CIN85 serine^threonine
phosphorylation, conformational changes within these mole-
cules, and additionally a competition with other CIN85 bind-
Fig. 3. CIN85 is coupled to clathrin-coated vesicles via interaction
with Dab2. A: NIH SAA cells were left unstimulated (3) or stimu-
lated with 100 ng/ml of EGF for 5 min. Cell lysates were subjected
to GST-pull down with either an empty GST or GST-3SH3 and
GST-PCc constructs of CIN85, and after recovery of the bound ma-
terial, detection was performed by immunoblotting with anti-clathrin
heavy chain and anti-Dab2 antibodies. The lower panel shows the
levels of used GST constructs (Ponceau staining). B: Cell lysates of
293T cells transfected with the wild-type Dab2 or the R699A mu-
tant were subjected to GST-pull downs with CIN85 GST-3SH3, and
analyzed as in Fig. 3A.
C
Fig. 4. Dab2 dissociates from CIN85 following ligand stimulation and is replaced by Cbl. A: HEK 293T cells transiently transfected with
CIN85 and Dab2 were left unstimulated (3) or stimulated with 100 ng/ml of EGF for the indicated time periods. Cell lysates were immunopre-
cipitated with anti-CIN85 or anti-FLAG antibodies, and after recovery of the bound material, detection was performed by immunoblotting
with the indicated antibodies. B: NIH SAA cells were left unstimulated (3) or stimulated with EGF for 10 min. Cell lysates were immunopre-
cipitated (IP) either with pre-immune serum (Pre) or anti-CIN85 antibodies, and detection was performed by immunoblotting (IB) with anti-
Dab2 or anti-CIN85 antibodies. C,D: Peptide competition assay. Lysates of 293T cells transfected with CIN85 and Dab2 (C), or with Dab2
alone (D) were incubated with increasing amounts (100 and 200 nmol) of indicated peptides for 1 h. Subsequently, the lysates were immunopre-
cipitated with anti-CIN85 antibodies (C), or subjected to GST-pull down with the GST-CIN85-SH3-B construct (D), and immunoblotted with
anti-CIN85 or anti-FLAG antibodies. E: HEK 293T cells were transiently transfected with CIN85, Dab2 and Cbl: wild-type (WT) or R829A
mutant, impaired in its ability to interact with CIN85. Cells were left unstimulated (3) or stimulated with 100 ng/ml of EGF for 10 min (+).
Cell lysates were immunoprecipitated with anti-CIN85 or anti-FLAG antibodies, and after recovery of the bound material, detection was per-
formed by immunoblotting with indicated antibodies. F: Schematic model of Dab2/CIN85 interaction during EGFR internalization. In the ab-
sence of EGF, cell surface-localized Dab2 binds to CIN85 and clathrin. Following early phases of cell stimulation, Dab2 positions CIN85 in
the vicinity of forming clathrin-coated pits where activated EGFR undergoes internalization. Activated receptors also bind to and phosphory-
late Cbl, which can in turn recruit CIN85 to receptor complexes, and thus cause dissociation of Dab2-CIN85 interactions. CIN85 bound to
EGFR/Cbl complexes may regulate subsequent steps in receptor endocytosis and their sorting for degradation in the lysosome.
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ing proteins. To verify the last hypothesis, we checked
whether Cbl-derived high a⁄nity peptide 814 [12] is able to
compete with Dab2 for binding to CIN85. Increasing amounts
of peptide 814, but not of arginine mutant R829A peptide,
e⁄ciently competed for the Dab2/CIN85 interaction. The
same e¡ect was observed when the peptide was added to the
lysates of cells transfected with both Dab2 and CIN85, or
when it was incubated together with Dab2-transfected cell
lysates and CIN85 GST-SH3B construct (Fig. 4C,D). Impor-
tantly, Dab2/CIN85 complex dissociated following EGF stim-
ulation in the presence of ectopic Cbl, whereas no such e¡ect
was observed when Cbl R829A, impaired in its ability to bind
to CIN85, was used instead (Fig. 4E). Moreover, overexpres-
sion of Cbl R829A prevented competition between endoge-
nous Cbl and Dab2 and resulted in constitutive CIN85/
Dab2 association (Fig. 4E). The binding between CIN85
and Dab2 was already impaired in the presence of overex-
pressed wild-type Cbl in unstimulated cells, as also in these
conditions binding between CIN85 and Cbl was very strong,
probably due to high tyrosine phosphorylation of overex-
pressed Cbl (Fig. 4E).
Taken together, our data suggest that Dab2 transiently
links CIN85 with clathrin complexes during receptor internal-
ization. Recruitment of Cbl to activated receptors, as well as
potential receptor-mediated protein modi¢cations such as
phosphorylation, might lead to increased binding between
CIN85 and Cbl, and disruption of a Dab2-CIN85 complex
following growth factor stimulation (Fig. 4F).
4. Discussion
Clathrin-mediated endocytosis is involved in lipid and pro-
tein tra⁄cking in eukaryotic cells from the plasma membrane,
trans-Golgi network and endosomes [20]. Clathrin oligomeri-
zation is the most important force for vesicle formation, but
the process requires additional interactions with multiple ac-
cessory proteins, which coordinate coat assembly and disas-
sembly, cargo recruitment, or provide link to the cytoskeleton
[21,22]. The best-characterized component of clathrin-coated
vesicles is a heterotetrameric adaptor complex AP-2, which
binds simultaneously to clathrin, to the internalization motifs
on the cargo, and recruits numerous accessory proteins to the
forming vesicles [22]. Many of these proteins exhibit them-
selves properties of endocytic adaptors, due to their abilities
to bind both clathrin and di¡erent cargo proteins. For exam-
ple, Dab2 binds to clathrin, AP-2, and additionally to the
internalization motifs on the LDL receptor [13,16]. Moreover,
Dab2 provides a potential link between receptor endocytosis
and cytoskeleton by binding to myosin VI, a motor protein
implicated in the movement of clathrin-coated vesicles along
actin ¢laments into the cell interior [23].
Here we demonstrate that CIN85, previously shown to be
critical for RTK endocytosis [8], can indirectly associate with
clathrin, mainly due to its SH3 domains binding to the pro-
line^arginine motif in Dab2 (Fig. 3A,B). Dab2 contains three
proline-rich sequences in the C-terminal part. The ¢rst two
motifs were found to be responsible for the interaction with
Src and Grb2, respectively, while no binding partner for the
third motif ; PKPAPR, has been identi¢ed so far [19,24]. Here
we show that this sequence, also preserved in the brain-spe-
ci¢c Dab2 homolog: Dab1, serves as a recognition region for
the SH3 domains of CIN85. All three SH3 domains of CIN85
bind to Dab2 to the similar extend, and when the double or
all three CIN85-SH3 domains are included within one con-
struct, association with Dab2 is increased (Fig. 1C). These
observations suggest that CIN85 could cluster Dab2 mole-
cules on clathrin-coated pits, which might result in the for-
mation of high a⁄nity CIN85-Dab2-clathrin agglomerates.
Importantly, a conserved PxxxPR motif is also present in
Cbl/Cbl-b and other CIN85 e¡ectors [12]. This implies that
while some of the CIN85-SH3 domains’ e¡ectors might be
components of the same protein complexes, others could com-
pete for association with CIN85. One way to regulate the
dynamic exchange of these e¡ectors could be by growth fac-
tor-dependent protein modi¢cations, such as phosphorylation
or protein conformational changes. Dab2 dissociates from
CIN85 upon growth factor stimulation (Fig. 4A,B), while
CIN85-Cbl binding is dramatically increased under the same
conditions [8]. Accordingly, Cbl can compete with Dab2 for
binding to the SH3 domains of CIN85 (Fig. 4C^E). Therefore
we propose that following receptor activation, Dab2 in com-
plex with CIN85 can be replaced by the high a⁄nity CIN85-
SH3 domains’ ligands, such as Cbl (Fig. 4F). Subsequently,
the CIN85-Cbl-EGFR complex is internalized and sorted for
lysosomal degradation [11], while Dab2 may remain at the
plasma membrane due to its PTB domain-mediated phospho-
inositide interactions [13], (Fig. 4F). In accordance with our
model, Dab2 has been shown to associate with clathrin tran-
siently, being absent from the early endosomal compartments
[16]. However, the exact mechanism behind growth factor-de-
pendent Dab2-CIN85 interaction still remains obscure, and
constitutes an interesting ¢eld for future investigations.
Dab2 is known to act as a tumor suppressor, able to inhibit
growth of many cancer types [25,26]. One of its growth-inhib-
itory e¡ects is mediated by the ability of Dab2 to downregu-
late EGF-induced signaling pathways, competing for binding
between SOS and Grb2, or inhibiting Src activity and thus
suppressing MAP kinase activation [18,19]. It remains to be
elucidated whether Dab2 exerts its growth-inhibitory func-
tions additionally by in£uencing RTK endocytosis.
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